Plant Name: Corydalis ternata
Taxonomic Information:
Plant ID: NPO25345
Plant Latin Name: Corydalis ternata
Taxonomy Genus: Corydalis
Taxonomy Family: Papaveraceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Unknown.
Geographical Distribution:
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; HTR7; HTR5A; ADRA1A; ADRA2B; DRD3; DRD1; DRD2; HTR2B; HTR2A; HTR1A; HTR6; | |
| ACHE; | |
| TDP1; ADK; | |
| CREBBP; | |
| LMNA; F3; THPO; SIGMAR1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Bromodomain | CREBBP | CREB-binding protein | Q92793 | CHEMBL5747 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | ADRA1A | Alpha-1a adrenergic receptor | P35348 | CHEMBL229 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | F3 | Coagulation factor III | P13726 | CHEMBL4081 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | SIGMAR1 | Sigma opioid receptor | Q99720 | CHEMBL287 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.859E-13 | 2.024E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.859E-13 | 2.024E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7 |
| MF | Unclassified; | GO:0004872; receptor activity | 4.117E-13 | 4.268E-10 | ADORA1, ADORA2A, ADORA3, ADRA1A, ADRA2B, DRD1, DRD2, DRD3, F3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 6.909E-13 | 6.018E-10 | HTR1A, HTR2A, HTR2B, HTR5A, HTR7 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.301E-12 | 1.789E-09 | ADORA1, ADORA2A, ADORA3, ADRA1A, ADRA2B, DRD1, DRD2, DRD3, HTR1A, HTR2A, HTR2B, HTR5A, HTR6, HTR7, SIGMAR1 |
| BP | GO:0050896; response to stimulus | GO:0060134; prepulse inhibition | 1.084E-09 | 5.621E-07 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 3.214E-09 | 1.428E-06 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 5.894E-09 | 2.468E-06 | HTR1A, HTR5A, HTR7 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 7.306E-09 | 2.841E-06 | DRD1, DRD2, DRD3, HTR2A |
| BP | GO:0050896; response to stimulus | GO:0001975; response to amphetamine | 2.244E-08 | 7.755E-06 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0001659; temperature homeostasis | 4.704E-08 | 1.484E-05 | ADORA1, DRD1, DRD2, HTR2A |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 5.145E-08 | 1.581E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 8.226E-08 | 2.184E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.233E-07 | 3.158E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 2.418E-07 | 5.916E-05 | DRD2, DRD3, HTR2B |
| BP | GO:0032501; multicellular organismal process | GO:0035815; positive regulation of renal sodium excretion | 4.185E-07 | 9.492E-05 | ADORA2A, DRD2, DRD3 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 4.185E-07 | 9.492E-05 | DRD1, DRD2, DRD3 |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 5.322E-07 | 1.159E-04 | ADORA1, DRD2, HTR2A |
| BP | GO:0009987; cellular process | GO:0071880; adenylate cyclase-activating adrenergic receptor signaling pathway | 1.659E-06 | 3.219E-04 | ADRA1A, ADRA2B, DRD2 |
| BP | GO:0065007; biological regulation | GO:0007202; activation of phospholipase C activity | 2.936E-06 | 5.156E-04 | ADRA1A, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 3.039E-06 | 5.295E-04 | ADRA1A, DRD2, HTR2A, HTR2B, THPO |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 4.066E-06 | 6.758E-04 | DRD2, DRD3 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 4.066E-06 | 6.758E-04 | ADORA1, ADORA2A |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 4.738E-06 | 7.317E-04 | DRD2, DRD3, HTR2A |
| BP | GO:0008152; metabolic process | GO:0030817; regulation of cAMP biosynthetic process | 5.123E-06 | 7.667E-04 | ADORA2A, DRD1, DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0043266; regulation of potassium ion transport | 5.123E-06 | 7.667E-04 | ADORA1, DRD1, DRD2, HTR2A |
| BP | GO:0065007; biological regulation | GO:0045777; positive regulation of blood pressure | 6.486E-06 | 9.479E-04 | ADORA1, ADRA1A, ADRA2B |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.353E-05 | 1.684E-03 | DRD1, DRD2 |
| BP | GO:0040011; locomotion | GO:0090325; regulation of locomotion involved in locomotory behavior | 1.353E-05 | 1.684E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0042321; negative regulation of circadian sleep/wake cycle, sleep | 1.353E-05 | 1.684E-03 | ADORA1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.353E-05 | 1.684E-03 | HTR2A, HTR2B |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 1.614E-05 | 1.910E-03 | ADORA1, ADORA2A, DRD1, DRD2, DRD3, HTR2A, HTR2B, HTR5A, HTR6 |
| BP | GO:0065007; biological regulation | GO:0045776; negative regulation of blood pressure | 1.642E-05 | 1.920E-03 | ADORA1, DRD2, DRD3 |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 2.025E-05 | 2.220E-03 | DRD2, HTR2A, HTR2B |
| BP | GO:0051179; localization | GO:0043271; negative regulation of ion transport | 2.163E-05 | 2.343E-03 | ADORA1, DRD2, DRD3, HTR2A |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 2.463E-05 | 2.578E-03 | DRD1, DRD2, DRD3 |
| BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 3.057E-05 | 3.097E-03 | ADORA1, ADORA2A, DRD1, DRD2 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 3.781E-05 | 3.709E-03 | DRD2, DRD3 |
| CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 4.858E-05 | 4.520E-03 | ADORA1, ADORA2A |
| BP | GO:0023052; signaling | GO:0046888; negative regulation of hormone secretion | 5.589E-05 | 5.114E-03 | ADORA1, ADRA2B, DRD2 |
| BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 5.806E-05 | 5.267E-03 | ADORA1, CREBBP, DRD3, HTR2A, HTR2B |
| BP | GO:0009987; cellular process | GO:0007191; adenylate cyclase-activating dopamine receptor signaling pathway | 6.068E-05 | 5.415E-03 | DRD1, DRD3 |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 6.068E-05 | 5.415E-03 | DRD2, DRD3 |
| BP | GO:0032501; multicellular organismal process | GO:0030432; peristalsis | 6.068E-05 | 5.415E-03 | DRD1, DRD2 |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 7.411E-05 | 6.455E-03 | DRD2, DRD3 |
| BP | GO:0032502; developmental process | GO:0021756; striatum development | 7.411E-05 | 6.455E-03 | DRD1, DRD2 |
| BP | GO:0032501; multicellular organismal process | GO:0007416; synapse assembly | 7.663E-05 | 6.648E-03 | ACHE, DRD1, DRD2 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 8.141E-05 | 6.979E-03 | ADORA1, ADORA2A, DRD2, SIGMAR1 |
| BP | GO:0007610; behavior | GO:0007625; grooming behavior | 8.887E-05 | 7.471E-03 | DRD1, DRD2 |
| BP | GO:0065007; biological regulation | GO:0045741; positive regulation of epidermal growth factor-activated receptor activity | 8.887E-05 | 7.471E-03 | ADORA1, ADRA2B |
| BP | GO:0009987; cellular process | GO:0051896; regulation of protein kinase B signaling | 1.041E-04 | 8.464E-03 | DRD2, DRD3, F3, THPO |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.049E-04 | 8.464E-03 | ADORA2A, ADRA1A |
| BP | GO:0009987; cellular process | GO:0033604; negative regulation of catecholamine secretion | 1.049E-04 | 8.464E-03 | ADRA2B, DRD2 |
| BP | GO:0009987; cellular process | GO:0060158; phospholipase C-activating dopamine receptor signaling pathway | 1.049E-04 | 8.464E-03 | DRD1, DRD2 |
| BP | GO:0009987; cellular process | GO:0014048; regulation of glutamate secretion | 1.223E-04 | 9.653E-03 | ADORA1, ADORA2A |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 5.026E-21 | 3.066E-19 | HTR1A, HTR2B, HTR2A, HTR5A, ADRA2B, ADRA1A, HTR6, HTR7, ADORA2A, ADORA3, ADORA1, DRD1, DRD2, DRD3 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04020 | Calcium signaling pathway | 1.609E-11 | 4.907E-10 | HTR6, HTR7, ADORA2A, HTR2B, HTR2A, DRD1, HTR5A, ADRA1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.252E-11 | 6.613E-10 | HTR6, HTR7, CYP2D6, HTR1A, HTR2B, HTR2A, HTR5A |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.861E-09 | 2.838E-08 | CREBBP, HTR6, ADORA2A, ADORA1, HTR1A, DRD1, DRD2 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 2.906E-06 | 3.546E-05 | HTR2B, HTR2A, DRD1, DRD2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 3.668E-05 | 3.730E-04 | ADORA3, ADORA1, ADRA2B, ADRA1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 4.224E-04 | 3.681E-03 | DRD1, DRD2, DRD3 |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05012 | Parkinson's disease | 5.592E-04 | 4.264E-03 | ADORA2A, DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05034 | Alcoholism | 1.094E-03 | 7.417E-03 | ADORA2A, DRD1, DRD2 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.440E-03 | 8.782E-03 | DRD1, DRD2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; DRD3; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA1A; ADORA1; ADORA2A; DRD1; DRD2; HTR1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| NA: NA | Hyperaemia | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; HTR2A; HTR6; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; HTR2A; HTR1A; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; DRD3; HTR1A; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; ADORA1; ADORA2A; DRD1; DRD2; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADRA1A; ACHE; ADORA2A; DRD1; DRD2; ADK; HTR1A; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | F3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADRA1A; ACHE; ADORA1; DRD1; HTR6; HTR1A; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR1A; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| C00-D49: Neoplasms | Chronic myeloid leukemia | NA | CREBBP; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; HTR2A; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B; |
| NA: NA | Cervical dystonia | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | ADRA1A; |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | ADRA1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; ADK; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; ADORA3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | HTR7; ADRA1A; DRD2; HTR1A; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HTR1A; |
| NA: NA | Episode | NA | HTR1A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; HTR2A; HTR2B; HTR1A; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; ADRA2B; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; DRD2; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; HTR6; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | ADRA1A; HTR1A; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2A; HTR2B; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; HTR6; |
| J00-J99: Diseases of the respiratory system | Adult respiratory distress syndrome | J80 | F3; |
| NA: NA | Addiction | NA | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Benign prostatic hyperplasia | N40 | ADRA1A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| NA: NA | Itching | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B; |
| NA: NA | False perceptions | NA | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| NA: NA | Vomiting | NA | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; DRD3; HTR6; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ADRA1A; DRD3; HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HTR7; HTR2A; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Post-traumatic stress disorder | F43.1 | ADRA1A; |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| N00-N99: Diseases of the genitourinary system | Stress urinary incontinence | N39.3 | ADRA1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HTR2A; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADRA1A; ACHE; ADORA1; ADORA2A; ADORA3; DRD2; HTR2A; |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; DRD2; HTR2A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| NA: NA | Social phobia | NA | HTR1A; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A; |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; HTR6; HTR1A; |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2A; HTR1A; |
| NA: NA | Schizoaffective disorder | NA | HTR1A; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| NA: NA | Anxiety disorders | NA | HTR1A; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR7; DRD1; DRD2; DRD3; HTR2A; HTR6; HTR1A; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | CREBBP; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; ADORA3; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; DRD2; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| NA: NA | Bulimia nervosa | NA | HTR1A; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
